Stock Research for ACET

ACET

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACET Stock Chart & Research Data

The ACET chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACET chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACET Due diligence Resources & Stock Charts

The ACET stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACET Detailed Price Forecast - CNN Money CNN View ACET Detailed Summary - Google Finance
Yahoo View ACET Detailed Summary - Yahoo! Finance Zacks View ACET Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACET Trends & Analysis - Trade-Ideas Barrons View ACET Major Holders - Barrons
NASDAQ View ACET Call Transcripts - NASDAQ Seeking View ACET Breaking News & Analysis - Seeking Alpha
Spotlight View ACET Annual Report - CompanySpotlight.com OTC Report View ACET OTC Short Report - OTCShortReport.com
TradeKing View ACET Fundamentals - TradeKing Charts View ACET SEC Filings - Bar Chart
WSJ View Historical Prices for ACET - The WSJ Morningstar View Performance/Total Return for ACET - Morningstar
MarketWatch View the Analyst Estimates for ACET - MarketWatch CNBC View the Earnings History for ACET - CNBC
StockMarketWatch View the ACET Earnings - StockMarketWatch MacroAxis View ACET Buy or Sell Recommendations - MacroAxis
Bullish View the ACET Bullish Patterns - American Bulls Short Pains View ACET Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACET Stock Mentions - StockTwits PennyStocks View ACET Stock Mentions - PennyStockTweets
Twitter View ACET Stock Mentions - Twitter Invest Hub View ACET Investment Forum News - Investor Hub
Yahoo View ACET Stock Mentions - Yahoo! Message Board Seeking Alpha View ACET Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACET - SECform4.com Insider Cow View Insider Transactions for ACET - Insider Cow
CNBC View ACET Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACET - OTC Markets
Yahoo View Insider Transactions for ACET - Yahoo! Finance NASDAQ View Institutional Holdings for ACET - NASDAQ


Stock Charts

FinViz View ACET Stock Insight & Charts - FinViz.com StockCharts View ACET Investment Charts - StockCharts.com
BarChart View ACET Stock Overview & Charts - BarChart Trading View View ACET User Generated Charts - Trading View




Latest Financial News for ACET


Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Posted on Monday April 22, 2024

REDWOOD CITY, Calif. & BOSTON, April 22, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the AS


Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Posted on Monday April 08, 2024

REDWOOD CITY, Calif. & BOSTON, April 08, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.


Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Posted on Thursday March 28, 2024

REDWOOD CITY, Calif. & BOSTON, March 28, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.


Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
Posted on Thursday March 21, 2024

Key Insights Adicet Bio's estimated fair value is US$3.65 based on 2 Stage Free Cash Flow to Equity Adicet Bio is...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.